Classement en actions
#16839
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in... Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS (central nervous system), oncology, and hematology disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases; and ORY-4001, a selective HDAC-6 inhibitor for the treatment of neurological disorders, such as Charcot-Marie-Tooth disease (CMT), amyotrophic lateral sclerosis (ALS), and others. It also has collaborations in precision medicine with Columbia University in New York and the Institute of Medical and Molecular Genetics (INGEMM) at La Paz Hospital in Madrid psychometrically characterize patients with mutations in the SetD1A or Shank3 genes; and Cooperative Research and Development Agreement (CRADA) to sponsor several clinical trials. The company was incorporated in 2000 and is based in Cornellà de Llobregat, Spain.
Prix de l'action
$3.31
Dernière synchronisation: 2026-09-01
Capitalisation boursière
$271.03M
Changement (1 jour)
-0.36%
Échange Oryzon Genomics S.A. (ORY)
Nombre d'actions en circulation pour Oryzon Genomics S.A. (ORY)
Nombre d'actions en circulation au September 2026: 0
Selon les derniers rapports financiers et le cours de l'action de Oryzon Genomics S.A., le nombre actuel d'actions en circulation est de 0. À la fin de September 2026, l'entreprise avait 0 actions en circulation. Le nombre d'actions en circulation est généralement affecté par les divisions d'actions et les rachats d'actions.
Historique des actions en circulation de Oryzon Genomics S.A. (ORY) de 2026 à 2026
Actions en circulation à la fin de chaque année
| Année |
Actions en circulation |
Changez |
|
Pas assez de données pour les dates fournies. |
Actions en circulation pour des entreprises similaires ou concurrentes
| Entreprise |
Actions en circulation |
Différence |
Pays |
|
|
253.90M |
-
|
US
|
|
|
62.19M |
-
|
NL
|
|
|
396.00M |
-
|
US
|
|
|
478.91M |
-
|
AU
|
|
|
- |
-
|
CH
|
